Market Overview

UPDATE: Ascendiant Capital Markets Reiterates Buy Rating, Lowers PT on StemCells

Related STEM
Valeant CEO Addresses Investor Concerns In Letter; Will It Help The Stock Price?
StemCells, Inc. Transplants First Patient in Phase II Clinical Trial for Dry Age-Related Macular Degeneration

In a report published Monday, Ascendiant Capital Markets reiterated its Buy rating on StemCells (NASDAQ: STEM), but slightly lowered its price target from $2.60 to $2.25.

Ascendiant Capital noted, “The Company ended the quarter with cash of $22 MM. Thus far in Q4, they have raised an additional $5.6 MM in cash from the exercise of warrants and sale of additional shares via their ATM facility. We are decreasing our Q4 2012 GAAP EPS, and 2013 GAAP EPS estimate, to reflect the higher number of shares outstanding. For Q4, our EPS estimate is lowered by $0.03 to ($0.15), and for 2013, our EPS estimate is decreased by $0.11 to ($0.58).”

StemCells closed on Friday at $1.76.

Latest Ratings for STEM

May 2015Cantor FitzgeraldInitiates Coverage onBuy
May 2015H.C WainwrightInitiates Coverage onBuy
Nov 2012Ascendiant Capital MarketsMaintainsBuy

View More Analyst Ratings for STEM
View the Latest Analyst Ratings

Posted-In: Ascendiant Capital MarketsAnalyst Color Price Target Analyst Ratings


Related Articles (STEM)

View Comments and Join the Discussion!

Get Benzinga's Newsletters